Article thumbnail

Gastrointestinal Complications in 147 Consecutive Patients with Peritoneal Surface Malignancy Treated by Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy

By Angela Casado-Adam, Robert Alderman, O. Anthony Stuart, David Chang and Paul H. Sugarbaker

Abstract

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used in the treatment of peritoneal carcinomatosis from gastrointestinal malignancies. The purpose of this study is to reevaluate the incidence of gastrointestinal events and identify risk factors associated with this treatment approach. Between January 1, 2006 and December 31, 2009, 147 patients with appendiceal and colorectal carcinomatosis were treated. Gastrointestinal events were analyzed. The overall incidence of grade I–IV gastrointestinal events was 17%. There were 4 grade III gastrointestinal events that occurred in 4 patients and 11 grade IV gastrointestinal events that occurred in 8 patients. On univariate analysis of grade I–IV events a statistically significant association was observed with the following variables: histological grade, peritoneal cancer index (PCI), small bowel resection, colorectal anastomosis, and the number of anastomoses performed per patient. By multivariate analysis, PCI was identified as the only independent risk factor for gastrointestinal complications. CRS combined with a uniform HIPEC regimen is associated with a 17% gastrointestinal morbidity rate (grade I–IV). The frequency of gastrointestinal complications was associated with a large extent of disease measured by PCI (>30)

Topics: Clinical Study
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:3263671
Provided by: PubMed Central

Suggested articles

Citations

  1. (1996). a h t e m e
  2. (2009). a n s s o n ,W .G r a f ,L
  3. (2010). a r a t t i ,S .K u s a m u r a ,A .D .C a b r a s ,B .L a t e r z a
  4. (1996). A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor,” in Peritoneal Carcinomatosis: Principles of
  5. (2009). A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin,”
  6. (2007). A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma,”
  7. (2005). Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion,”
  8. (2006). Common Terminology Criteria for adverse events v3.0 (CTAE), Cancer Therapy Evaluation Program,
  9. (1996). Current methodologies for clinical assessment of patients with peritoneal carcinomatosis,”
  10. (2006). Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion. Analysis of morbidity and mortality in 209 peritoneal surface malignanciestreatedwithclosedabdomentechnique,”Cancer,
  11. (2006). Decision-making and technical factors account for the learning curve in complex surgery,”
  12. (2003). Gastrectomy, peritonectomy and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer,”
  13. (2010). Hyperthermic intraperitonealchemotherapyinovariancancer:firstreportof the HYPER-O registry,”
  14. (2004). Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin,”
  15. (2003). Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures,”
  16. (2000). It’s what the surgeon doesn’t see that kills the patient,”
  17. (2009). l i a s ,J .H .L e f e v r e ,J .C h e v a l i e re ta l . ,“ C o m p l e t ec y t o r e -ductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin,”
  18. (2007). Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a Nationally Funded Peritonectomy Center,”
  19. (2007). Learning curve of combined modality treatment in peritoneal surface disease,”
  20. (2006). Management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy,”
  21. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin,”
  22. P.H.Sugarbaker,“Fivereasonswhycytoreductivesurgeryplus hyperthermicintraperitonealchemotherapymustberegarded as the new standard of care for diffuse malignant peritoneal mesothelioma,”
  23. (2010). Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy,”
  24. (2000). Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study,”
  25. (2009). Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy,”
  26. (1995). Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy,”
  27. (2003). Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer,”
  28. (2005). Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal
  29. (2007). Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer,”
  30. (1997). The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation,”
  31. (2009). The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrentovariancancer,”Clinical and Translational Oncology,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.